Adagene announced that China's NMPA has approved its Investigational New Drug (IND) application for ADG138, a bispecific T cell engager. This approval allows Adagene to proceed with a Phase 1 clinical trial for advanced solid tumors, which is expected to begin in Q4 2026, marking a significant step in the drug's development.
Adagene announced the NMPA approval of its IND application for ADG138, a double-masked HER2×CD3 bispecific T cell engager. This approval is a crucial regulatory milestone, allowing the company to initiate a Phase 1 clinical trial in China for advanced solid tumors, projected for Q4 2026. This news is positive for Adagene as it validates their proprietary SAFEbody technology and moves a promising drug candidate closer to market. While the immediate market impact might be moderate given the early stage of development (Phase 1), it represents a long-term opportunity for the company if ADG138 demonstrates efficacy and safety in human trials. The key risk lies in the lengthy and uncertain clinical trial process, but this approval is a de-risking event for the initial development phase.